DEFA14A: Ekso Bionics Issues Supplement to Proxy Statement to Correct Year Reference for Director Elections

Ekso Bionics has released a supplement to its definitive proxy statement to correct the year reference for the term of directors elected at the upcoming annual meeting.

Summary

• Ekso Bionics Holdings, Inc. filed a supplement to its definitive proxy statement on Schedule 14A.
• The supplement corrects the year reference in descriptions of the proposal relating to the election of directors.
• The original proxy statement incorrectly stated that elected directors would serve until the 2024 annual meeting, instead of the 2025 meeting.
• The company has replaced the language describing Proposal One in the Notice and on page 1 of the Proxy Statement to reflect this correction.
• The Annual Meeting of Stockholders will be held on June 6, 2024, at 9:00 a.m. PDT.
• The corrected proposal states that the five elected directors will serve until the annual meeting of stockholders to be held in 2025.

Sentiment

Score: 7

Explanation: The document is a routine correction of a minor error in the proxy statement, indicating a neutral sentiment.

Industry Context

This announcement is a routine correction to a proxy statement, which is a common occurrence in corporate governance.

Stakeholder Impact

• Shareholders are provided with corrected information regarding the term of service for elected directors.

Key Dates

Keywords

Proxy Statement, Ekso Bionics, Annual Meeting, Board of Directors, Director Election, Supplement